These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 7584508

  • 1. Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with diminished release of pro-inflammatory cytokines.
    Abbs IC, Clark M, Waldmann H, Chatenoud L, Koffman CG, Sacks SH.
    Ther Immunol; 1994 Dec; 1(6):325-31. PubMed ID: 7584508
    [Abstract] [Full Text] [Related]

  • 2. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
    Woodle ES, Bruce DS, Josephson M, Cronin D, Newell KA, Millis JM, Piper JB, O'Laughlin R, Thistlethwaite JR.
    Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115
    [Abstract] [Full Text] [Related]

  • 3. Novel humanized anti-CD3 antibodies induce a predominantly immunoregulatory profile in human peripheral blood mononuclear cells.
    Silva HM, Vieira PM, Costa PL, Pimentel BM, Moro AM, Kalil J, Maranhão AQ, Coelho V, Brigido MM.
    Immunol Lett; 2009 Aug 15; 125(2):129-36. PubMed ID: 19573559
    [Abstract] [Full Text] [Related]

  • 4. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells.
    Cole MS, Anasetti C, Tso JY.
    J Immunol; 1997 Oct 01; 159(7):3613-21. PubMed ID: 9317161
    [Abstract] [Full Text] [Related]

  • 5. Fc receptor binding of anti-CD3 monoclonal antibodies is not essential for immunosuppression, but triggers cytokine-related side effects.
    Vossen AC, Tibbe GJ, Kroos MJ, van de Winkel JG, Benner R, Savelkoul HF.
    Eur J Immunol; 1995 Jun 01; 25(6):1492-6. PubMed ID: 7614975
    [Abstract] [Full Text] [Related]

  • 6. Immunologic monitoring with Orthoclone OKT3 therapy.
    Schroeder TJ, First MR, Hurtubise PE, Marmer DJ, Martin DM, Mansour ME, Melvin DB.
    J Heart Transplant; 1989 Jun 01; 8(5):371-80. PubMed ID: 2529358
    [Abstract] [Full Text] [Related]

  • 7. Anti-CD3 and -CD4 monoclonal antibody in the treatment of steroid-resistant renal allograft rejection.
    Wang XH, Xie T.
    Chin Med J (Engl); 1993 Nov 01; 106(11):821-4. PubMed ID: 8143493
    [Abstract] [Full Text] [Related]

  • 8. In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants.
    Parlevliet KJ, ten Berge IJ, Yong SL, Surachno J, Wilmink JM, Schellekens PT.
    J Clin Invest; 1994 Jun 01; 93(6):2519-25. PubMed ID: 8200988
    [Abstract] [Full Text] [Related]

  • 9. Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody.
    Li J, Davis J, Bracht M, Carton J, Armstrong J, Gao W, Scallon B, Fung R, Emmell E, Zimmerman M, Griswold DE, Li L.
    Int Immunopharmacol; 2006 Jun 01; 6(6):880-91. PubMed ID: 16644473
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo.
    Alegre ML, Peterson LJ, Xu D, Sattar HA, Jeyarajah DR, Kowalkowski K, Thistlethwaite JR, Zivin RA, Jolliffe L, Bluestone JA.
    Transplantation; 1994 Jun 15; 57(11):1537-43. PubMed ID: 8009586
    [Abstract] [Full Text] [Related]

  • 12. Immunosuppressive properties of anti-CD3 single-chain Fv and diabody.
    Le Gall F, Reusch U, Moldenhauer G, Little M, Kipriyanov SM.
    J Immunol Methods; 2004 Feb 01; 285(1):111-27. PubMed ID: 14871540
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Fibrinoid necrosis of a temporal artery complicating the treatment of refractory cardiac allograft rejection with murine monoclonal CD3 antibody (OKT3).
    Hammond EH, Watson FS, Bristow MR, O'Connell JB, Gilbert EM, Doty DB, Renlund DG.
    J Heart Transplant; 1990 Feb 01; 9(3 Pt 1):236-8. PubMed ID: 2113090
    [Abstract] [Full Text] [Related]

  • 15. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection.
    Woodle ES, Xu D, Zivin RA, Auger J, Charette J, O'Laughlin R, Peace D, Jollife LK, Haverty T, Bluestone JA, Thistlethwaite JR.
    Transplantation; 1999 Sep 15; 68(5):608-16. PubMed ID: 10507477
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Structured to reduce the mitogenicity of anti-CD3 antibody based on computer-guided molecular design.
    Lv M, Li Y, Yu M, Sun Y, Lin Z, Qiao C, Luo Q, Gu X, Huang Y, Feng J, Shen B.
    Int J Biochem Cell Biol; 2007 Sep 15; 39(6):1142-55. PubMed ID: 17446118
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. First and second course of OKT3 monoclonal anti-T cell antibody for treatment of renal allograft rejection followed by testing for anti-OKT3 IgM and/or IgG immunization.
    Birkeland SA, Bach JF, Chatenoud L, Jørgensen KA, Strate M, Elbirk A, Rohr N, Svendsen V.
    Transplant Proc; 1990 Feb 15; 22(1):221-2. PubMed ID: 2106740
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.